Trial Profile
Clinical study of the drug CF-MEV-107 for the treatment of fistulizing Crohn's disease refractory to conventional therapies
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 24 May 2018
Price :
$35
*
At a glance
- Drugs CF-MEV-107 (Primary)
- Indications Crohn's disease
- Focus Adverse reactions; First in man; Therapeutic Use
- 24 May 2018 New trial record
- 17 May 2018 According to an ESPERITE media release, this clinical trial will be performed in Italy at Padua University Hospital in collaboration with the Women's and Children's Health Department of the University of Padua.